Generics BulletinHBW InsightIn VivoMedtech InsightPink SheetScrip

Generics Bulletin

Medtech Insight

Biosimilars: Next User Fee Cycle Will Be Judged On US FDA's Approvals, Rep. Burgess Says

Mar 15 2017

• By Derrick Gingery

Human antibody

Related Content

FDA Gets Broad Exemptions From Federal Hiring Freeze In HHS Memo

Feb 10 2017

Pending Biosimilars

Feb 13 2017

US FDA Commissioner Confirmation: Gottlieb To Get Questions On Approval Standards, Ties To Industry

Mar 13 2017

CDER Director Woodcock Plans Changes To Drug Reviews During OND Transition

Mar 07 2017

US Generic Reviews: Would Pre-Submission Meetings Be Better Than Six-Month Priority Review?

Mar 06 2017

Show Me The Money: Salaries, Red Tape Challenge FDA Recruiting

Jan 19 2015

Biosimilars Will Get PDUFA-Style Reviews Under New User Fee Plan

Sep 28 2016

Biosimilar Interchangeability May Be Losing Luster As Approval Goal

Sep 13 2016

Biosimilar User Fee Agreement Offers FDA Funding Boost, Fee Structure Overhaul

Sep 17 2016

Additional Topics

United States Biosimilars FDA Regulation Biologics Pricing Debate BioPharmaceutical

More from Biosimilars

More from Products

Twitter feed RSS feed RSS feed

About UsOpens in new window
Meet the TeamOpens in new window
RSS FeedOpens in new window

Contact Us
Customer Service
Subscribe
AdvertisingOpens in new window
Feedback

Terms and ConditionsOpens in new window

Privacy PolicyOpens in new window